The framework links U.S. drug prices to international benchmarks through manufacturer agreements and federal pricing mechanisms, with major implications for high-cost drugs like GLP-1s.

Study finds widespread use of no-cost screenings, with estimated annual savings exceeding $4,000 per family.

Regulators are facing pressure to act in the growing disagreement over claims-data requirements.

Allison De Paoli is a relentless advocate for transparent, high-impact employee benefits, driven by the belief that benefits are "not just numbers on a spreadsheet," she rejects the industry's status quo to deliver creative, fiduciary-first solutions that prioritize both fiscal health and human dignity.

Pharmaceutical Strategies Group survey finds employers and health plans prioritizing cost control and cross-benefit management, with growing willingness to trade rebates for stronger utilization oversight amid rising complexity and CGT concerns.

Physicians warn rapid adoption is outpacing oversight, urging transparency, crisis protections and clearer rules as demand grows amid persistent gaps in care.

A judge ruled disputes must be resolved within the No Surprises Act process, not retried in court.

The incident comes as the health care sector remains on edge after Brian Thompson's murder.